Company intelligence / Profile preview

Vanway Pharmaceutical Holdings

Ownership: Private
Development stage: Other

Overview

Vanway Pharmaceutical Holdings develops and manufactures biological drugs. Its lead product Analgecine (“Extracts from Rabbit Skin Inflamed by Vaccinia Virus for Injection”) has been approved in China since December 2003 as a treatment for neuralgia and various forms of musculoskeletal pain. The drug acts via modulation of serotonin receptors and antagonism of bradykinin receptors. It remains under clinical investigation for expanded indications including intervertebral disc disease and acute ischemic stroke. The company’s manufacturing operations are based in Rugao, Jiangsu province.

Therapeutic areas: RheumatologyNeurologyCardiovascular
Modalities: Biological productsSmall molecule
Industry: Biotech

Beyond the preview

Go deeper on Vanway Pharmaceutical Holdings.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Vanway Pharmaceutical Holdings.

Explore the full profile